Scilex Holding (SCLX) Asset Writedowns and Impairment (2024)
Scilex Holding (SCLX) posted quarterly Asset Writedowns and Impairment of $14.8 million for Q4 2024, up 1183.32% on a QoQ basis from $1.2 million in Q2 2024.
Scilex Holding (SCLX) Asset Writedowns and Impairment (2024) Analysis & Trends
Scilex Holding (SCLX) has reported Asset Writedowns and Impairment for 1 consecutive years, with $14.8 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM figure through Dec 2024 stood at $17.3 million (changed N/A YoY), while the FY2024 annual figure was $17.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at $14.8 million for Q4 2024 at Scilex Holding, up from $1.2 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $14.8 million in Q4 2024, with the low at $1.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 14.77 Mn |
| Dec 31, 2024 | 14.77 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |